vs
Embecta Corp.（EMBC）与OneStream, Inc.（OS）财务数据对比。点击上方公司名可切换其他公司
Embecta Corp.的季度营收约是OneStream, Inc.的1.6倍（$261.2M vs $163.7M），Embecta Corp.净利率更高（16.9% vs 0.6%，领先16.3%），OneStream, Inc.同比增速更快（23.6% vs -0.3%），OneStream, Inc.自由现金流更多（$25.6M vs $16.6M），过去两年OneStream, Inc.的营收复合增速更高（21.8% vs -4.6%）
Embecta Corp.是一家专注于糖尿病护理领域的全球医疗科技企业，主要设计、生产及销售胰岛素笔针、注射器、输注组件等给药装置，产品服务覆盖全球多个地区的患者、医疗机构及生物制药合作方。
Blue Stream面向美国佛罗里达州科勒尔斯普林斯、韦斯顿两地的居民及商业客户，提供有线电视、有线固话、数字录像服务，以及最高速率达1G的宽带互联网接入服务，深耕当地通信市场，为用户提供稳定可靠的多元通信解决方案。
EMBC vs OS — 直观对比
营收规模更大
EMBC
是对方的1.6倍
$163.7M
营收增速更快
OS
高出23.9%
-0.3%
净利率更高
EMBC
高出16.3%
0.6%
自由现金流更多
OS
多$9.0M
$16.6M
两年增速更快
OS
近两年复合增速
-4.6%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $261.2M | $163.7M |
| 净利润 | $44.1M | $999.0K |
| 毛利率 | 61.9% | 69.8% |
| 营业利润率 | 31.9% | -3.2% |
| 净利率 | 16.9% | 0.6% |
| 营收同比 | -0.3% | 23.6% |
| 净利润同比 | — | — |
| 每股收益（稀释后） | $0.74 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收EMBCOS
| Q4 25 | $261.2M | $163.7M | ||
| Q3 25 | $264.0M | $154.3M | ||
| Q2 25 | $295.5M | $147.6M | ||
| Q1 25 | $259.0M | $136.3M | ||
| Q4 24 | $261.9M | $132.5M | ||
| Q3 24 | $286.1M | $129.1M | ||
| Q2 24 | $272.5M | $117.5M | ||
| Q1 24 | $287.2M | $110.3M |
净利润EMBCOS
| Q4 25 | $44.1M | $999.0K | ||
| Q3 25 | $26.4M | $-8.8M | ||
| Q2 25 | $45.5M | $-18.4M | ||
| Q1 25 | $23.5M | $-24.0M | ||
| Q4 24 | $0 | — | ||
| Q3 24 | $14.6M | $-171.9M | ||
| Q2 24 | $14.7M | $-7.8M | ||
| Q1 24 | $28.9M | $-5.0M |
毛利率EMBCOS
| Q4 25 | 61.9% | 69.8% | ||
| Q3 25 | 60.0% | 68.1% | ||
| Q2 25 | 66.7% | 68.6% | ||
| Q1 25 | 63.4% | 68.0% | ||
| Q4 24 | 60.0% | 66.8% | ||
| Q3 24 | 60.7% | 50.1% | ||
| Q2 24 | 69.8% | 68.5% | ||
| Q1 24 | 64.6% | 69.1% |
营业利润率EMBCOS
| Q4 25 | 31.9% | -3.2% | ||
| Q3 25 | 21.4% | -11.3% | ||
| Q2 25 | 31.8% | -21.8% | ||
| Q1 25 | 24.3% | -29.3% | ||
| Q4 24 | 11.0% | -35.8% | ||
| Q3 24 | 9.2% | -197.6% | ||
| Q2 24 | 20.5% | -9.8% | ||
| Q1 24 | 13.6% | -4.9% |
净利率EMBCOS
| Q4 25 | 16.9% | 0.6% | ||
| Q3 25 | 10.0% | -5.7% | ||
| Q2 25 | 15.4% | -12.5% | ||
| Q1 25 | 9.1% | -17.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | 5.1% | -133.1% | ||
| Q2 24 | 5.4% | -6.7% | ||
| Q1 24 | 10.1% | -4.5% |
每股收益（稀释后）EMBCOS
| Q4 25 | $0.74 | — | ||
| Q3 25 | $0.44 | — | ||
| Q2 25 | $0.78 | — | ||
| Q1 25 | $0.40 | — | ||
| Q4 24 | $0.00 | — | ||
| Q3 24 | $0.24 | $-1.06 | ||
| Q2 24 | $0.25 | — | ||
| Q1 24 | $0.50 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $201.3M | $693.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $-613.1M | $504.7M |
| 总资产 | $1.1B | $1.0B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资EMBCOS
| Q4 25 | $201.3M | $693.6M | ||
| Q3 25 | $225.5M | $653.9M | ||
| Q2 25 | $230.6M | $652.1M | ||
| Q1 25 | $209.3M | $593.9M | ||
| Q4 24 | $210.0M | $544.2M | ||
| Q3 24 | $267.5M | $495.5M | ||
| Q2 24 | $275.1M | $140.5M | ||
| Q1 24 | $299.8M | — |
总债务EMBCOS
| Q4 25 | — | — | ||
| Q3 25 | $1.4B | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $1.6B | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益EMBCOS
| Q4 25 | $-613.1M | $504.7M | ||
| Q3 25 | $-650.6M | $472.1M | ||
| Q2 25 | $-669.6M | $458.2M | ||
| Q1 25 | $-736.2M | $412.9M | ||
| Q4 24 | $-768.8M | $386.2M | ||
| Q3 24 | $-738.3M | $458.2M | ||
| Q2 24 | $-763.7M | $97.5M | ||
| Q1 24 | $-769.6M | $102.5M |
总资产EMBCOS
| Q4 25 | $1.1B | $1.0B | ||
| Q3 25 | $1.1B | $949.4M | ||
| Q2 25 | $1.2B | $910.5M | ||
| Q1 25 | $1.1B | $867.3M | ||
| Q4 24 | $1.1B | $823.2M | ||
| Q3 24 | $1.3B | $750.1M | ||
| Q2 24 | $1.3B | $379.7M | ||
| Q1 24 | $1.2B | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $17.2M | $25.8M |
| 自由现金流经营现金流 - 资本支出 | $16.6M | $25.6M |
| 自由现金流率自由现金流/营收 | 6.4% | 15.7% |
| 资本支出强度资本支出/营收 | 0.2% | 0.1% |
| 现金转化率经营现金流/净利润 | 0.39× | 25.79× |
| 过去12个月自由现金流最近4个季度 | $205.8M | $95.6M |
8季度趋势，按日历期对齐
经营现金流EMBCOS
| Q4 25 | $17.2M | $25.8M | ||
| Q3 25 | $84.0M | $5.0M | ||
| Q2 25 | $81.2M | $29.7M | ||
| Q1 25 | $31.8M | $36.2M | ||
| Q4 24 | $-5.3M | — | ||
| Q3 24 | $26.6M | $2.4M | ||
| Q2 24 | $-2.1M | $8.1M | ||
| Q1 24 | $24.3M | $25.5M |
自由现金流EMBCOS
| Q4 25 | $16.6M | $25.6M | ||
| Q3 25 | $76.7M | $4.8M | ||
| Q2 25 | $80.8M | $29.4M | ||
| Q1 25 | $31.7M | $35.8M | ||
| Q4 24 | $-6.8M | — | ||
| Q3 24 | — | $1.3M | ||
| Q2 24 | $-11.8M | $7.7M | ||
| Q1 24 | $20.9M | $24.9M |
自由现金流率EMBCOS
| Q4 25 | 6.4% | 15.7% | ||
| Q3 25 | 29.1% | 3.1% | ||
| Q2 25 | 27.3% | 19.9% | ||
| Q1 25 | 12.2% | 26.3% | ||
| Q4 24 | -2.6% | — | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | -4.3% | 6.6% | ||
| Q1 24 | 7.3% | 22.5% |
资本支出强度EMBCOS
| Q4 25 | 0.2% | 0.1% | ||
| Q3 25 | 2.8% | 0.1% | ||
| Q2 25 | 0.1% | 0.2% | ||
| Q1 25 | 0.0% | 0.3% | ||
| Q4 24 | 0.6% | — | ||
| Q3 24 | 0.0% | 0.8% | ||
| Q2 24 | 3.6% | 0.3% | ||
| Q1 24 | 1.2% | 0.6% |
现金转化率EMBCOS
| Q4 25 | 0.39× | 25.79× | ||
| Q3 25 | 3.18× | — | ||
| Q2 25 | 1.78× | — | ||
| Q1 25 | 1.35× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.82× | — | ||
| Q2 24 | -0.14× | — | ||
| Q1 24 | 0.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
EMBC
| Pen Needles | $185.5M | 71% |
| Safety | $37.3M | 14% |
| Syringes | $30.7M | 12% |
| Manufacturing Facility | $4.1M | 2% |
OS
| Subscription And Circulation | $150.3M | 92% |
| Professional Services And Other | $9.4M | 6% |
| License | $4.0M | 2% |
